Skip to main content

Affinity Asset Advisors, LLC

SEC CIK
0001773195
Latest filing
Aug 13, 2026

Holdings in Q2 2022

Holdings as of Jun 30, 2022, filed Aug 12, 2022. Long positions only; changes compare share counts with Q1 2022.

Institution overview
Positions
40
−8 vs. Q1 2022
Portfolio value
$182.6M
−$69.6M (−27.6%) vs. Q1 2022
Filed
Aug 12, 2022
SEC
Holdings of Affinity Asset Advisors, LLC in Q2 2022
SecurityClassSharesValue% of portfolioShare changeActionHistory
ESTAEstablishment Labs Holdings Inc.COM359,956$19.6M10.7%+185,456+106.3%AddedHistory
KURAKura Oncology, Inc.COM928,256$17.0M9.3%+4,109+0.4%AddedHistory
KDNYChinook Therapeutics, Inc.COM937,568$16.4M9.0%+92,413+10.9%AddedHistory
NARIInari Medical, Inc.Stock222,173$15.1M8.3%+2,173+1.0%AddedHistory
ASNDAscendis Pharma A/SSPONSORED ADR125,087$11.6M6.4%+5,087+4.2%AddedHistory
Retrophin Inc761299AB2NOTE 2.500% 9/1–$10.9M6.0%–––
LNTHLantheus Holdings, Inc.Stock140,000$9.24M5.1%+25,000+21.7%AddedHistory
Nanostring Technologies Inc63009RAD1NOTE 2.625% 5/0–$8.02M4.4%–––
MDGLMadrigal Pharmaceuticals, Inc.COM100,000$7.16M3.9%+25,000+33.3%AddedHistory
HZNPHorizon Therapeutics Public Ltd CoSHS75,000$5.98M3.3%+45,000+150.0%AddedHistory
KRTXKaruna Therapeutics, Inc.COM45,000$5.69M3.1%+37,500+500.0%AddedHistory
AZNAstraZeneca PLCSPONSORED ADR85,000$5.62M3.1%−75,000−46.9%ReducedHistory
MORFMorphic Holding, Inc.COM215,723$4.68M2.6%−249,931−53.7%ReducedHistory
Bellus Health Inc New07987C204COM NEW493,278$4.56M2.5%−106,722−17.8%Reduced–
RPTXRepare Therapeutics Inc.COM321,200$4.49M2.5%−147,705−31.5%ReducedHistory
BridgeBio Pharma, Inc.10806XAD4NOTE 2.250% 2/0–$4.24M2.3%–––
BridgeBio Pharma, Inc.10806XAB8NOTE 2.500% 3/1–$4.15M2.3%–––
CBAYCymaBay Therapeutics, Inc.COM1,372,244$4.05M2.2%+100,000+7.9%AddedHistory
RCKTRocket Pharmaceuticals, Inc.COM250,466$3.45M1.9%−49,534−16.5%ReducedHistory
ARYEARYA Sciences Acquisition Corp VCLASS A ORD SHS352,500$3.43M1.9%−350,000−49.8%ReducedHistory
ZNTLZentalis Pharmaceuticals, Inc.COM70,000$1.97M1.1%−137,500−66.3%ReducedHistory
CNTXContext Therapeutics Inc.COM883,654$1.87M1.0%+106,044+13.6%AddedHistory
VINCVincerx Pharma, Inc.COM NEW1,374,098$1.81M1.0%00.0%UnchangedHistory
ACRSAclaris Therapeutics, Inc.COM100,000$1.40M0.8%00.0%UnchangedHistory
ACLXArcellx, Inc.COMMON STOCK75,000$1.36M0.7%+75,000NewHistory
NAUTNautilus Biotechnology, Inc.COM466,607$1.25M0.7%−92,412−16.5%ReducedHistory
COGTCogent Biosciences, Inc.COM125,000$1.13M0.6%+125,000NewHistory
CLDXCelldex Therapeutics, Inc.COM NEW40,000$1.08M0.6%−85,000−68.0%ReducedHistory
TERNTerns Pharmaceuticals, Inc.COM401,268$995.0K0.5%+401,268NewHistory
LIANYLianBioSPONSORED ADS450,000$972.0K0.5%+125,000+38.5%AddedHistory
SPRYARS Pharmaceuticals, Inc.COM170,000$721.0K0.4%+170,000NewHistory
CYTKCytokinetics IncCOM NEW15,000$589.0K0.3%+15,000NewHistory
SNCEScience 37 Holdings, Inc.COM279,775$562.0K0.3%+58,393+26.4%AddedHistory
RCORRenovacor, Inc.COM199,490$405.0K0.2%00.0%UnchangedHistory
Immatics N.V.N44445117*W EXP 07/01/202187,204$382.0K0.2%00.0%Unchanged–
CRISCuris IncCOM NEW340,349$335.0K0.2%−9,651−2.8%ReducedHistory
VRDNViridian Therapeutics, Inc.COM20,660$239.0K0.1%−29,340−58.7%ReducedHistory
PNTPOINT Biopharma Global Inc.COM25,578$174.0K0.1%+25,578NewHistory
Medicus Sciences AcquisitionG5960S124*W EXP 02/12/20233,333$8.00K<0.1%00.0%Unchanged–
Renovacor, Inc.75989E114*W EXP 99/99/99975,000$5.00K<0.1%00.0%Unchanged–

Options (13)

Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.

Option positions of Affinity Asset Advisors, LLC in Q2 2022
SecurityClassPutsCalls
LLYEli Lilly & CoStock–$9.73M
NVAXNovavax IncCOM NEW$4.63M$4.37M
ESTAEstablishment Labs Holdings Inc.COM$8.16M–
KRTXKaruna Therapeutics, Inc.COM$5.69M–
LNTHLantheus Holdings, Inc.Stock$4.62M–
CRSPCRISPR Therapeutics AGNAMEN AKT–$4.25M
CLDXCelldex Therapeutics, Inc.COM NEW–$3.91M
LEGNLegend Biotech CorpSPONSORED ADS–$2.75M
MRNAModerna, Inc.Stock–$2.14M
FATEFate Therapeutics IncCOM–$1.67M
IOVAIovance Biotherapeutics, Inc.COM–$1.66M
CELUCelularity IncCOM CL A$624.0K–
LNAILunai Bioworks Inc.COM$386.0K–

Sold out since Q1 2022 (14)

Positions held at the end of Q1 2022 that are gone from this filing.

Positions of Affinity Asset Advisors, LLC sold out since Q1 2022
SecurityClassShares in Q1 2022Value in Q1 2022% of portfolio in Q1 2022History
SWTXSpringWorks Therapeutics, Inc.COM247,000$13.9M5.5%History
PTGXProtagonist Therapeutics, IncCOM300,000$7.10M2.8%History
NSTGNS Wind Down Co., Inc.COM171,592$5.96M2.4%History
OBIOOrchestra BioMed Holdings, Inc.ORD SHS300,000$2.97M1.2%History
Medicus Sciences AcquisitionG5960S108CL A SHS300,000$2.93M1.2%–
TVTXTravere Therapeutics, Inc.COM100,000$2.58M1.0%History
CERECerevel Therapeutics Holdings, Inc.COM70,000$2.45M1.0%History
XENEXenon Pharmaceuticals Inc.COM80,000$2.45M1.0%History
GBTGlobal Blood Therapeutics, Inc.COM70,000$2.42M1.0%History
Bio Green Med Solution, Inc.23254L603COM400,000$1.22M0.5%–
CNTACentessa Pharmaceuticals plcSPONSORED ADS65,282$586.0K0.2%History
CALACalithera Biosciences, Inc.COM1,000,000$404.0K0.2%History
HYPRHyperfine, Inc.COM CL A76,162$270.0K0.1%History
BPMCBlueprint Medicines CorpCOM1,988$127.0K0.1%History